Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase I/II feasibility study

Radiation Oncology

Volumn 2, Issue 1, 2007, Pages

  Junius, Sara ^a   Haustermans, Karin ^a   Bussels, Barbara ^b   Oyen, Raymond ^a   Vanstraelen, Bianca ^a   Depuydt, Tom ^a   Verstraete, Jan ^a   Joniau, Steven ^a   Van Poppel, Hendrik ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b H Hartziekenhuis ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548548576     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-2-29     Document Type: Article

References (41)

1. Jones GW Mettlin C Murphy GP Guinan P Herr HW Hussey DH Chmiel JS Fremgen AM Clive RE Zuber-Ocwieja KE: Patterns of care for carcinoma of the prostate gland. Results of a national survey of 1984 and 1990. J Am Coll Surg 1995, 180:545-554. 7538405
2. Brenner DJ Hall EJ: Fractionation and protraction for radiotherapy of prostate carcinoma Int J Radiat Oncol Biol Phys 1999, 43(5):1095-1101. 10.1016/S0360-3016(98)00438-6 10192361
3. Fowler JP Chappell R Ritter M: Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001, 50(4):1021-1031. 10.1016/ S0360-3016(01)01607-8 11429230
4. Brenner DJ Martinez AA Edmundson GK Mitchell C Thames HD Armour EP: Direct evidence that prostate tumors show high sensivity to fractionation (low alpha/beta) comparable with late responding normal tissue. Int J Radiat Oncol Biol Phys 2002, 52(1):6-13. 10.1016/ S0360-3016(01)02664-5 11777617
5. Bentzen SM Ritter MA: The alpha/beta ratio for prostate cancer: What is it, really? Radiother Oncol 2005, 76:1-3. 10.1016/j.radonc.2005.06.009 15990189
6. Haustermans KM Hofland I Van Poppel H Oyen R Van de Voorde W Begg AC Fowler JF: Cell kinetics measurements in prostatic cancer. Int J Radiat Oncol Biol Phys 1997, 37:1067-1070. 10.1016/S0360-3016(96)00579-2 9169814
7. Haustermans K Fowler JF: A comment on proliferation rates in human prostate cancer (letter). Int J Radiat Oncol Biol Phys 2000, 48(1):297-297. 10.1016/S0360-3016(00)00562-9
8. Scrivner DL Meyer DS Rujanavech N Fathman A Scully T: Cell kinetics by bromodeoxyuridine labelling and deoxyribonucleic acid ploidy in prostatic carcinoma needle biopsies. J Urol 1991, 146:1034-1039. 1895419
9. Williams S Taylor J: Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 2007, 68(1):24-33. 17448868
10. Van der Kogel AJ Jarrett KA Paciotti MA Raju MR: Radiation tolerance of the rat rectum fractionated X-Rays and pimesons. Radiother Oncol 1988, 12:225-232. 10.1016/0167-8140(88)90265-4 3175049
11. Brenner DJ: Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys 2004, 60:1013-1015. 10.1016/j.ijrobp.2004.04.014 15519768
12. Stuschke M Thames HDl Fractionation sensitivities and dose-control relations of head and neck carcinomas: Analysis of the randomized hyperfractionation trials. Radiother Oncol 1999, 51:113-121. 10.1016/ S0167-8140(99)00042-0 10435801
13. American Society for Therapeutic Radiology and Oncology Consensus Panel: Consensus Statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997, 37:1035-1041. 10.1016/ S0360-3016(97)00002-3 9169810
14. American Society for Therapeutic Radiology and Oncology Consensus Panel: PSA Relapse Definitions. Radiology and Oncology. New Orleans, LA, American Society for Therapeutics: 2002.
15. Chueng R Tucker SL Lee AL Dong L Kamat A Pisters L Kuban DA: Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 61(1):14-9. 2005; jan 1 10.1016/j.ijrobp.2004.04.064 15629589
16. Williams SG Duchesne GM Gogna NK Millar JL Pickles T Pratt GR Turner S: An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer risk Int J Radiat Oncol Biol Phys 65(2):351-7. 2006 June 1 10.1016/j.ijrobp.2005.12.007 16530339
17. Storey MR Pollack A Zagers G Smith L Antolak J Rosen I: Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000, 48:635-642. 10.1016/S0360-3016(00)00700-8 11020558
18. Fleming TR One-sampling multiple testing procedure for phase II clinical trials Biometrics 1982, 38:143-151. 10.2307/2530297 7082756
19. EORTC Quality of life group QLQ-C30 reference values. CD rom version 1.0 1998
20. Van der Gucht S Van Audenhove C: De beoordeling van de kwaliteit van leven van patienten met gelokaliseerde prostaatkanker. Evaluatie van een meetinstrument. Thesis Faculteit Psychologie en Pedagogische Wetenschappen 2004.
21. Fowler JF Ritter MA Chappell RJ Brenner DJ What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 2003, 56(4):1093-1104. 10.1016/S0360-3016(03)00132-9 12829147
22. Vanuytsel L Van Poppel H Adjuvant radiotherapy after radical prostatectomy Radiotherapy of prostate cancer. London, Harwood, GmbH Greco C, Zelefsky M 1999, 377-384.
23. Lloyd-Davies RW Collins CD Swan AV Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation: Twenty-two years' experience (1962-1984) Urology 1990 36:107-111 10.1016/ 0090-4295(90)80207-4 2385876
24. Logue JP Cowan RA Hendry JH: Hypofractionation for prostate cancer. Int J Radiat Oncol Biol Phys 2001, 49:1522-1523. 10.1016/ S0360-3016(00)01565-0 11293438
25. Duncan W Warde P Catton CN Murro AJ Lakier R Gadalla T Gospodarowicz MK: Carcinoma of the prostate: Results of radical radiotherapy (1970-1985). Int J Radiat Oncol Biol Phys 1993, 26:203-210. 8491678
26. Logue JP Hypofractionation for prostate cancer: Letter to the editor. Int J Radiat Oncol Biol Phys 2001, 49(5):1522-1522. 10.1016/ S0360-3016(00)01565-0 11293438
27. Peeters ST Heemsbergen WD Van Putten WL Slot A Tabak H Mens JW Lebesque JV Koper PC: Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter randomized trial comparing 68 to 78 Gy. Int J Radiat Oncol Biol Phys 2005, 61:1019-1034. 10.1016/ j.ijrobp.2004.07.715 15752881
28. Pollack A Hanlon AL Horwitz EM Feigenberg SJ Konski AA Mousas B Greenberg RE Uzzo RG Ma CM McNeeley SW Buyyounouski MK Price RA Jr Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 2006, 64(2):518-526. 1892754 16242256 10.1016/j.ijrobp.2005.07.970
29. Soete G Arcangeli S De Meerleer G Landoni V Fonteyne V Arcangeli G De Neve W Storme G: Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: Report on acute toxicity. Radiat Oncol 2006, 80(1):78-81. Epub 2006 Jul 7 10.1016/ j.radonc.2006.06.005
30. Lukka H Hayter CH Julian JA Warde P Morris WZ Gospodarowicz M Levine M Sathya J Choo R prichard H Brundage M Kwan W: Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology 2005, 23:6132-6138. 10.1200/JCO.2005.06.153 16135479
31. Kupelian PA Reddy CA Carlson TP Altsman KA Willoughby TR: Preliminary observations on biochemical relapse-free survival rates after short-course intensity modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys 2002, 53:904-912. 10.1016/S0360-3016(02)02836-5 12095556
32. Kupelian PA Reddy CA Klein EA Willoughby TR: Short-course intensity modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer: Preliminary results on late toxicity and quality of life Int J Radiat Oncol Biol Phys 2001, 51:988-993. 10.1016/S0360-3016(01)01730-8 11704322
33. Kupelian PA Thakkar VV Khuntia D Reddy CA Klein EA Mahadevan A: Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long term outcomes. Int J Radiat Oncol Biol Phys 2005, 63(5):1463-1468. 10.1016/ j.ijrobp.2005.05.054 16169683
34. Peeters ST Hoogeman MS Heemsbergen WD Slot A Tabak H Koper PC Lebesque JV: Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2005, 63(4):1142-1152. 10.1016/j.ijrobp.2005.03.060 15939547
35. Zelefsky MJ Harrison A: Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy. Urology 1997, 49:38-45. 10.1016/S0090-4295(97)00168-4 9123735
36. Tsai HK Manola J Abner A Talcott JA D'Amico AV Beard C: Patient-reported acute gastro-intestinal toxicity in men receiving 3-dimensional conformal radiation therapy for prostate cancer with or without neoadjuvant androgen suppression therapy. Urologic Oncology Seminars and Original investigations 2005, 23:230-237. 16018937
37. Joon DL Hasegawa M Sikes C Khoo VS Terry NH Zagars GK Meistrich ML Pollack A: Supraadditive apoptotic respone of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 1997, 38:1071-1077. 10.1016/S0360-3016(97)00303-9 9276374
38. Zietman AL Prince EA Nakfoor BM Park JJ: Androgen deprivation and radiation therapy; sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys 1997, 38:1067-1070. 10.1016/ S0360-3016(97)00309-X 9276373
39. Yeoh EE Fraser RJ Borg MF McGowan RE Botten RJ Di Matteo AC Roos DE Penniment MG Borg MF: Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: Early results of a Phase III randomized trial. Int J Radiat Oncol Biol Phys 2003, 55(4):943-955. 10.1016/S0360-3016(02)04146-9 12605972
40. Jani AB Gratzle J: Late radiotherapy toxicity after prostate cancer treatment: Influence of hormonal therapy Urology 2005, 66(3):566-70. 10.1016/j.urology.2005.03.081 16140079
41. Sanguineti G Agostinelli S Foppiano F Franzone P Garelli S Marcenaro M Orsatti M Vitale V: Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy for prostate carcinoma. Br J Cancer 2002, 86:1843-1847. 10.1038/sj.bjc.6600266 12085173